US Oncology has accrued more than 32,000 cancer patients into clinical trials.

In addition, the company has played a pivotal role in the FDA approval of 24 anticancer drugs.

This unrivaled national research platform can become a vital part of any physician's practice - through US Oncology's Cancer Research Services. If qualifications for these services are met, a cost-effective research program can be built that includes access to nationwide Phase I-IV clinical trials and new investigational molecules. US Oncology is currently collaborating with leading pharmaceutical and biotechnology companies in more than 65 trials involving chemotherapy, immunotherapy, stem cell transplantation and gene therapy.

US Oncology's unique research infrastructure includes dedicated professional staff plus a single standardized Institutional Review Board approval process. Through this highly efficient organization, drugs are sped from the research lab into the real world, reaching patients as quickly as possible.